The anti-inflammatory effect of ent-kaur-15-en-17-al-18-oic acid on lipopolysaccharide-stimulated RAW264.7 cells associated with NF-κB and P38/MAPK pathways. Issue 6 (3rd June 2021)

• Record Type: Journal Article
• Authors: Zhang, Cai-Yun; Lin, Shi-Qi; Liu, Fang-Yuan; Ma, Jia-Hui; Jia, Fu-Juan; Han, Zhuo; Xie, Wei-Dong; Li, Xia
• Is Part Of: Journal of Asian natural products research. Volume 23:Issue 6(2021)
• Page Start: 570
• Page End: 583
• Publication Date: 2021-06-03
• Subjects: Ent-kaur-15-en-17-al-18-oic acid -- inflammation -- LPS -- migration -- P38 -- NF-κB; Materia medica -- Asia -- Periodicals; Pharmacognosy -- Asia -- Periodicals; Medicinal plants -- Asia -- Periodicals; Medicine, Oriental -- Asia -- Periodicals; 615.321095
• DOI: 10.1080/10286020.2020.1786371
• Languages: English
• ISSNs: 1028-6020

Abstract

Abstract: Ent -kaur-15-en-17-al-18-oic acid (LL-3) was demonstrated that it can inhibit LPS-induced nitric oxide (NO) production and macrophage migration, maintain homeostasis of oxidative stress, including increased mitochondrial membrane potential (MMP), decreased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and maintenance of superoxide dismutase (SOD) and glutathione (GSH) activities and inhibit oxidative stress-induced P38 and nuclear factor κB (NF-κB) pathways to decrease inducible nitric oxide synthase (iNOS), cyclooxygense-2 (COX-2), and tumour necrosis factor (TNF)-α mRNA expressions without marked cytotoxicity. These findings revealed that LL-3 could serve as a candidate lead compound for further studying anti-inflammatory therapies.